Sign up
Oil Capital

Haydale Graphene opens Taiwanese operations to meet demand for conductive inks and pastes

The operation is located in Kaohsiung, Southern Taiwan
Diabetes test
Graphene-based inks and pastes can be used in devices used to diagnose diabetes

Haydale Graphene Industries PLC (LON:HAYD), the advanced materials group, has established operations in Taiwan.

Haydale Technologies (Taiwan) will operate as a dedicated producer and sales outlet of graphene-based conductive inks and pastes, including other functional and speciality inks and pastes.

Haydale said it has largely completed the set-up of its own dedicated ink production facility to meet anticipated demand.

READ: Haydale Graphene Industries – Capital Network: The Tipping Point

The company will initially be targeting the self-monitoring blood glucose (SMBG) diagnostic device market, as several such Taiwanese products in the testing phase have incorporated Haydale's inks; these Haydale customers are moving down the path of seeking regulatory approval to sell the diagnostic products in the USA.

Haydale expects the first sales of these products will be recorded later this year. 

Diabetes sufferers expected to increase to 640 mln worldwide by 2040

According to market research firm Research & Markets, the SMBG device market is expected to grow to more than US$16bn by 2020 as the incidence of diabetes is increasing dramatically, with more than 640 mln sufferers estimated worldwide by 2040.

WATCH: Haydale Graphene's Ray Gibbs hails 'massive' order book after company restructure

At present, highly conductive inks and pastes tend to use metal-based inks incorporating silver and copper, but graphene is expected to make inroads into this market, as it offers many advantages, such as recyclability, lower unit costs and the fact that the material is not susceptible to volatile market price movements.

"The development of our graphene-based inks has been focused on the screen printing market for over three years, which started with Haydale being awarded an Innovate UK grant for the production of ink for the self-monitoring blood glucose device market,” revealed Ray Gibbs, chief executive officer of Haydale.

“Three years later we have expectations on securing sales this calendar year and the necessary FDA [Food & Drug Administration] and regulatory approvals through dedicated printers such that we were confident to open a operation facility in Taiwan to service our collaboration partners' needs. The biomedical sensor market is massive and we consider that the Far East has a significant portion of this growing sector. I look forward to making more announcements on progress in ink sales over the coming months," he added.

Why Invest In Haydale Graphene Industries PLC? Read More Here

Register here to be notified of future HAYD Company articles
View full HAYD profile View Profile
View All

Related Articles

© oil Capital 2018

Oil Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed oil companies to interact with institutional and highly capitalised investors.
Headquartered in London, Oil Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Technology market.